Pfizer says that it believes partially inhibiting CETP, as its pill does, will still produce effective HDL. A recent paper by Pfizer researchers in the journal Arteriosclerosis, Thrombosis, and Vascular Biology does seem to bolster Pfizer's case.

FORBES: Pfizer's Big Bet

The Corporate Library paper argues that too many former private equity companies reach the public markets with anti-takeover poison pill provisions, board seats for the former owners and executive compensation plans that don't serve shareholders.

FORBES: Magazine Article

Translating medical research into practice is never easy, but Dr. Ben Abella, a co-author on the Circulation paper and the clinical research director of the Center for Resuscitation Science, says that hypothermia is an especially hard pill for some to swallow.

CNN: Cooling is catching on for cardiac arrest patients